Select country change
Shopping cart (0 , 0,00 ) Menu Search
Distributed product

N-MID® Osteocalcin ELISA

  • Regulatory status:RUO
  • Type:Sandwich ELISA, HRP-labelled antibody
  • Other names:OST, bone Gla protein, B.G.P
  • Species:Human
Please select your region to see available products and prices.
Cat. No. Size Price


AC-11F1 96 wells
PubMed Product Details
Technical Data

Type

Sandwich ELISA, HRP-labelled antibody

Description

The N-MID® Osteocalcin ELISA is an enzyme immunological test for the quantitative measurement of osteocalcin, an indicator of osteoblastic activity in human serum and plasma and is intended to be used as an aid in the prevention of osteoporosis. Determination of serum osteocalcin has proved to be valuable as an aid in identifying women at risk of developing osteoporosis, for monitoring bone metabolism during the perimenopause and postmenopause and during anti-resorptive therapy.

Scientific Description:

Osteocalcin, or bone Gla protein (BGP), is the major non-collagenous protein of bone matrix. It has a molecular weight of approximately 5800 Dalton and consists of 49 amino acids, including three residues of gamma-carboxyglutamic acid. Osteocalcin is synthesised in bone by osteoblasts. After production, it is partly incorporated into the bone matrix and partly delivered to the circulatory system. The precise physiological function of osteocalcin is still unclear. A large number of studies have shown that the circulating level of osteocalcin reflects the rate of bone formation. The N-MID® Osteocalcin ELISA is based upon the application of two highly specific monoclonal antibodies (mAbs) against human osteocalcin. An antibody recognising the mid-region (amino acids 20-29) is used as the capture antibody, and for detection a peroxidase conjugated antibody recognising the N-terminal region (amino acids 10-16) is used. In addition to intact osteocalcin (amino acids 1-49) the N terminal mid-fragment (amino acids 1-43) is also detected.

Applications

Serum, Plasma

Sample Requirements

20 μL/well

Storage/Expiration

Store the complete kit at 2-8°C. Under these conditions, the kit is stable until the expiration date (see label on the box).

Calibration Range

0-100 ng/mL

Limit of Detection

0.5 ng/mL Osteocalcin

Summary

Features

  • Easy to perform
  • The N-MID® Osteocalcin ELISA recognises both intact and large N-Mid® osteocalcin fragments with equal affinity
  • N-MID® Osteocalcin ELISA measuring total osteocalcin is more stable and reproducible than assays measuring intact osteocalcin only
  • Robust assay format
  • Excellent correlation with automated methods

Research topic

Bone and cartilage metabolism

Summary

Osteocalcin or bone Gla protein (B.G.P) is the major non-collagen protein of the bone matrix. It has a molecular weight of 5800 Da and contains 49 amino-acids, including 3 residues of gamma carboxyl glutamic acid. Osteocalcin is synthesized in the bone by the osteoblasts. After production, it is partly incorporated in the bone matrix and the rest is found in the blood circulation. The exact physiological function of osteocalcin is still unclear. A large number of studies show that the circulating levels of osteocalcin reflect the rate of bone formation. The determination of the blood levels of osteocalcin is valuable for : - The identification of women at risk of developing osteoporosis - Monitoring bone metabolism during the perimenopause and postmenopause - Monitoring bone metabolism during hormone replacement therapy and treatment of premenopausal women with LH-RH agonists - Monitoring bone metabolism in patients with growth hormone deficiency, hypothyroidism, hyperthyroidism, chronic renal failure.

Summary References (8)

References to Osteocalcin

  • Brown JP, Delmas PD, Malaval L, Edouard C, Chapuy MC, Meunier PJ. Serum bone Gla-protein: a specific marker for bone formation in postmenopausal osteoporosis. Lancet. 1984 May 19;1 (8386):1091-3
  • Coleman RE, Mashiter G, Fogelman I, Whitaker KD, Caleffi M, Moss DW, Rubens RD. Osteocalcin: a potential marker of metastatic bone disease and response to treatment. Eur J Cancer Clin Oncol. 1988 Jul;24 (7):1211-7
  • Coulton LA, Preston CJ, Couch M, Kanis JA. An evaluation of serum osteocalcin in Paget's disease of bone and its response to diphosphonate treatment. Arthritis Rheum. 1988 Sep;31 (9):1142-7
  • Demiaux B, Arlot ME, Chapuy MC, Meunier PJ, Delmas PD. Serum osteocalcin is increased in patients with osteomalacia: correlations with biochemical and histomorphometric findings. J Clin Endocrinol Metab. 1992 May;74 (5):1146-51
  • Johansen JS, Jensen SB, Riis BJ, Rasmussen L, Zachmann M, Christiansen C. Serum bone Gla protein: a potential marker of growth hormone (GH) deficiency and the response to GH therapy. J Clin Endocrinol Metab. 1990 Jul;71 (1):122-6
  • Minisola S, Scarnecchia L, Scarda A, Bigi F, Tabolli S, Valtorta C, Mazzuoli G. Serum osteocalcin in primary hyperparathyroidism: short-term effect of surgery. Miner Electrolyte Metab. 1988;14 (4):201-7
  • Power MJ, Fottrell PF. Osteocalcin: diagnostic methods and clinical applications. Crit Rev Clin Lab Sci. 1991;28 (4):287-335
  • Price PA. Vitamin K-dependent formation of bone Gla protein (osteocalcin) and its function. Vitam Horm. 1985;42:65-108
Related Products Docs